Home » Stocks » CSTL

Castle Biosciences, Inc. (CSTL)

Stock Price: $69.18 USD 0.53 (0.77%)
Updated Jul 29, 2021 11:43 AM EDT - Market open
Market Cap 1.74B
Revenue (ttm) 68.04M
Net Income (ttm) -15.13M
Shares Out 25.06M
EPS (ttm) -0.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $69.18
Previous Close $68.65
Change ($) 0.53
Change (%) 0.77%
Day's Open 68.68
Day's Range 66.15 - 70.31
Day's Volume 20,137
52-Week Range 36.15 - 107.69

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #castlebiosciences--Castle Biosciences announced that it will release its financial results for the second quarter and six months ended June 30, 2021 on Aug...

3 days ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #AHNS--Castle Biosciences announced a podium presentation at the American Head & Neck Society (AHNS) 10th International Conference on Head and Neck Cancer.

6 days ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #SDPA--Castle Biosciences announced data presentations at the Society of Dermatology Physician Assistants (SDPA) Annual Summer Dermatology Conference 2021.

6 days ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #boardofdirectors--Castle announced that Kim Caple and Ellen Goldberg have been appointed to its board of directors, effective immediately.

1 week ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CHRON100--Castle has been included in the Houston Chronicle's list of the 100 most successful publicly traded companies in the Houston area.

1 month ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxSCC--Castle announced that it has received approval from the New York State Department of Health for its DecisionDx-SCC test.

1 month ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #BairdESGConference--Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatm...

1 month ago - Business Wire

SAN DIEGO, May 26, 2021   /PRNewswire/ -- AltheaDx, a commercial stage, precision medicine company with the world's leading pharmacogenomics test for anxiety and depression announced today that it has a...

2 months ago - PRNewsWire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #headquarters--Castle today announced it will host a ribbon cutting ceremony at its new corporate headquarters.

2 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #AmericanSkinAssociation--Castle today announced its collaboration with the American Skin Association to provide a 2021 research grant in the area of melanoma.

2 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #castlebiosciences--Castle today announced a publication describing the findings of a squamous cell carcinoma (SCC) gene expression profiling (GEP) expert p...

2 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #OpcoMedTech2021--Castle today announced that management will participate in the Oppenheimer MedTech, Tools, & Diagnostics Summit, May 26, 2021.

2 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #BoardofDirectors--Castle today announced that Tiffany Olson has been appointed to its board of directors, effective immediately.

2 months ago - Business Wire

Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of 22.73% and 33.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Shares of Castle Biosciences (NASDAQ:CSTL) were unchanged in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share decreased 666.67% over the past year to ($0....

2 months ago - Benzinga

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #castlebiosciences--Castle today announced its financial results for the first quarter ended March 31, 2021.

2 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #dermatologicdisease--Castle today announced its pipeline initiative to develop a genomic test aimed at predicting systemic therapy response.

2 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #GenomicTesting--Castle has been selected as the winner of the “Best New Technology Solution for Oncology.”

2 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #ARVO--Castle presented data on its 15-gene expression profile (15-GEP) test, DecisionDx®-UM, at ARVO 2021.

2 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #Melanoma--Castle Collaborates with the Colorado Melanoma Foundation and Epiphany Dermatology to Provide Free Skin Cancer Screenings Across the Southwest U.S.

2 months ago - Business Wire

Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #AmericanAcademyofDermatology--Castle today announced its national sponsorship of the American Academy of Dermatology's (AAD) "Skin Cancer, Take a Hike!"

2 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DiffDxMelanoma--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer tre...

3 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle will release its financial results for the first quarter 2021 and provide a pipeline update, after the close of market on May 10,...

3 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #AADVMX2021--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatme...

3 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DNANurses--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatmen...

3 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #10thWCM--Castle presented data on its three skin cancer gene expression profile tests at the 10th World Congress of Melanoma.

3 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle presented new data on the integration of the DecisionDx®-Melanoma test with clinicopathologic features (i31-GEP).

3 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer ...

3 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #Melanoma--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment...

3 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle announced it will collaborate with the Melanoma Research Foundation (MRF) to present “Ask the Expert” Managing Melanoma, a webina...

3 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer ...

3 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer...

4 months ago - Business Wire

The stock price of Castle Biosciences, a skin cancer diagnostic company, has seen a large 24% drop over the last ten trading days, while it is down 14% over the last five trading days. We believe the st...

4 months ago - Forbes

Castle Biosciences, Inc. (CSTL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pri...

4 months ago - Zacks Investment Research

Castle Biosciences, Inc. (CSTL) delivered earnings and revenue surprises of -45.45% and 10.62%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the st...

4 months ago - Zacks Investment Research

Shares of Castle Biosciences (NASDAQ:CSTL) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were down 254.55% year over year to ($0.17), whic...

4 months ago - Benzinga

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences Announces Fourth Quarter and Full-Year 2020 Results

4 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences Launches DecisionDx-Melanoma Integrated Test Result Utilizing Artificial Intelligence to Predict Individualized Risk

4 months ago - Business Wire

Castle Biosciences (CSTL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

4 months ago - Zacks Investment Research

Castle Biosciences, Inc. (CSTL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #SkinCancer--Castle will release its financial results for the fourth quarter and year-ended December 31, 2020, after the close of market on Monday, March 8...

5 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle Biosciences is scheduled to present a company overview at upcoming investor conferences.

5 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle today announced virtual posters on its three skin cancer gene expression profile tests at the 19th Annual South Beach Symposium.

5 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #DecisionDxMelanoma--Castle Biosciences to Present Data on DecisionDx®-Melanoma, DecisionDx® DiffDx™-Melanoma at 18th Annual Winter Clinical Dermatology Con...

6 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #Castle--Castle today announced certain unaudited preliminary performance results for the fourth quarter and full-year 2020.

6 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Castle is scheduled to present a company overview at the 23rd Annual Needham Virtual Growth Conference on Jan. 15, 2021.

6 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #skincancer--Castle today announced it prepaid in full its outstanding term loan facility.

7 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL--Castle Biosciences today announced the closing of its previously announced underwritten public offering.

7 months ago - Business Wire

FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL--Castle Biosciences announced today the pricing of its underwritten public offering.

7 months ago - Business Wire

About CSTL

Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, ... [Read more...]

Industry
Diagnostics & Research
IPO Date
Jul 25, 2019
Stock Exchange
NASDAQ
Ticker Symbol
CSTL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 5 analysts, the average rating for CSTL stock is "Strong Buy." The 12-month stock price forecast is 86.83, which is an increase of 25.51% from the latest price.

Price Target
$86.83
(25.51% upside)
Analyst Consensus: Strong Buy